HLS 10RS-1209 ORIGINAL

Regular Session, 2010

1

HOUSE BILL NO. 1073

BY REPRESENTATIVE MILLS

PHARMACISTS: Provides with respect to drugs of concern in the prescription monitoring program

AN ACT

2	To enact R.S. 40:1005(D) and (E), relative to the Prescription Monitoring Program; to
3	provide for drugs of concern; to provide for a timeline; to provide for reports and
4	recommendations; and to provide for related matters.
5	Be it enacted by the Legislature of Louisiana:
6	Section 1. R.S. 40:1005(D) and (E) are hereby enacted to read as follows:
7	§1005. Advisory council: recommendations for drugs of concern
8	* * *
9	D. Once a drug has been declared by the board to be a drug of concern, the
10	board shall have one year from the date of declaration to collect data on the drug,
11	make an assessment, and issue a report to the House and Senate committees on
12	health and welfare recommending one of the following:
13	(1) That the drug be declared a controlled dangerous substance pursuant to
14	R.S. 40:961 et seq.
15	(2) That the drug be removed from the list as a drug of concern.
16	E. In the event that, after one year, the board cannot make a determination
17	regarding a drug of concern as provided by Subsection D of this Section, the board
18	shall issue a report to the House and Senate committees on health and welfare
19	requesting more time for data collection and advising when a subsequent report with

CODING: Words in struck through type are deletions from existing law; words <u>underscored</u> are additions.

1 recommendations pursuant to Subsection D of this Section shall be submitted to the

2 <u>committees.</u>

3 * * *

DIGEST

The digest printed below was prepared by House Legislative Services. It constitutes no part of the legislative instrument. The keyword, one-liner, abstract, and digest do not constitute part of the law or proof or indicia of legislative intent. [R.S. 1:13(B) and 24:177(E)]

Mills HB No. 1073

Abstract: Provides relative to the Prescription Monitoring Program. Provides that once a drug is deemed by the La. Board of Pharmacy to be a drug of concern, the board, in consultation with the advisory council, shall have a year to gather data on the drug and make a recommendation in a report to the House Committee on Health and Welfare and the Senate Committee on Health and Welfare as to whether or not the drug should be declared a controlled dangerous substance or removed from the list as a drug of concern. If the board determines there is not enough information to make a recommendation after one year, the board may conduct further study and issue a later report of recommendations.

<u>Present law</u> provides that the La. Board of Pharmacy shall seek, and the advisory council of the Prescription Monitoring Program shall provide, information and advice regarding which drugs of concern should be monitored.

<u>Proposed law</u> retains <u>present law</u> but adds that once a drug has been deemed by the board to be a drug of concern, the board, in consultation with the advisory council shall have one year from the date of declaration to collect data on the drug, make an assessment, and issue a report to the House and Senate Committees on Health and Welfare as to whether or not the drug should be declared a controlled dangerous substance or removed from the list as a drug of concern.

<u>Proposed law</u> provides that if the La. Board of Pharmacy is unable to make a determination after one year whether or not a drug should be declared a controlled dangerous substance or removed from the list of drugs of concern, the board shall submit a report to the House and Senate Committees on Health and Welfare requesting more time for data collection and advising when a subsequent report with recommendations shall be submitted.

(Adds R.S. 40:1005(D) and (E))